Methods: Data on 62 patients with SS were collected from Acute Physiologic and Chronic Health Evaluation (APACHE) Outcome database and medical records
5% of a very large intravenous dose of ascorbic acid was recovered as urinary oxalic acid in people with normal renal function
Philosophy of the Hydrocortisone, Ascorbic Acid iHAT = intravenous hydrocortisone, ascorbic acid, thiamine Hrs = time from sepsis presentation to iHAT initiation O/E = observed/expected ICU mortality ratio using APACHE IV Background: Sepsis is a major public health burden resulting in 25% to 30% in-hospital mortality and accounting for over 20 billion dollars of US hospital costs
Several studies suggested that high-dose vitamin C reduced inflammatory reaction associated with sepsis and acute respiratory distress syndrome
1 The early physiology, pathology and laboratory measurements associated with these two vitamins and their deficiencies are described primarily through old diseases
The objective of this randomized, double-blind, placebo-controlled, phase I trial was to determine the safety of intravenously infused ascorbic acid in patients with severe sepsis
Given the known role of ascorbate in: a) maintaining endothelial and suppression of inflammatory markers; b) protection from sepsis in animal models; and c) direct antineoplastic effects, we propose the use of ascorbate as an adjuvant to existing After diagnosing sepsis or septic shock and a PCT level >7 ng/mL patients randomised to Group 2 were treated with intravenous vitamin C (ascorbic acid – Systochem Laboratories Ltd, India) (1
Ascorbic acid was administered at 25 mg/kg IV as a bolus (Ascor, McGruff Pharmaceuticals, Santa Ana, California), the dose of which was based on pharmacokinetic studies in horses and extrapolation from human sepsis studies
Preliminary data suggests that the combination of Hydrocortisone, Ascorbic Acid and Thiamine (HAT therapy) may reduce organ failure and mortality in patients with sepsis and septic shock
In this publication we describe a clinical protocol that has been developed over the past twenty years utilizing high dose
16-20 In animal models of sepsis, intravenous (IV) administration of AA supports
In our study, 23 septic patients were supplemented with a high dose (50 mg/kg every 6 h) of intravenous AA or placebo for 96 h